Cohance Lifesciences Limited (NSE: COHANCE.NS) Stock Competitors & Peer Comparison

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, SUNPHARMA.NS has a market cap of 4.6T. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while SUNPHARMA.NS trades at ₹1,902.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas SUNPHARMA.NS's P/E ratio is 36.95. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, COHANCE.NS is more volatile compared to SUNPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check SUNPHARMA.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, SUNPHARMA.BO has a market cap of 4.6T. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while SUNPHARMA.BO trades at ₹1,900.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas SUNPHARMA.BO's P/E ratio is 37.27. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, COHANCE.NS is more volatile compared to SUNPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check SUNPHARMA.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, DIVISLAB.NS has a market cap of 2.3T. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while DIVISLAB.NS trades at ₹8,597.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas DIVISLAB.NS's P/E ratio is 78.05. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to DIVISLAB.NS's ROE of +0.18%. Regarding short-term risk, COHANCE.NS is more volatile compared to DIVISLAB.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check DIVISLAB.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, DIVISLAB.BO has a market cap of 2.3T. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while DIVISLAB.BO trades at ₹8,550.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas DIVISLAB.BO's P/E ratio is 77.59. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to DIVISLAB.BO's ROE of +0.18%. Regarding short-term risk, COHANCE.NS is more volatile compared to DIVISLAB.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check DIVISLAB.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, TORNTPHARM.BO has a market cap of 1.9T. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while TORNTPHARM.BO trades at ₹4,880.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas TORNTPHARM.BO's P/E ratio is 74.06. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to TORNTPHARM.BO's ROE of +0.20%. Regarding short-term risk, COHANCE.NS is more volatile compared to TORNTPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check TORNTPHARM.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, TORNTPHARM.NS has a market cap of 1.9T. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while TORNTPHARM.NS trades at ₹4,896.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas TORNTPHARM.NS's P/E ratio is 73.37. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to TORNTPHARM.NS's ROE of +0.20%. Regarding short-term risk, COHANCE.NS is more volatile compared to TORNTPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check TORNTPHARM.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, CIPLA.BO has a market cap of 1.2T. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while CIPLA.BO trades at ₹1,426.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas CIPLA.BO's P/E ratio is 29.95. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to CIPLA.BO's ROE of +0.10%. Regarding short-term risk, COHANCE.NS is more volatile compared to CIPLA.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check CIPLA.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, CIPLA.NS has a market cap of 1.2T. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while CIPLA.NS trades at ₹1,432.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas CIPLA.NS's P/E ratio is 34.49. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to CIPLA.NS's ROE of +0.10%. Regarding short-term risk, COHANCE.NS is more volatile compared to CIPLA.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check CIPLA.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while ZYDUSLIFE.BO trades at ₹1,120.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas ZYDUSLIFE.BO's P/E ratio is 26.38. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to ZYDUSLIFE.BO's ROE of +0.16%. Regarding short-term risk, COHANCE.NS is more volatile compared to ZYDUSLIFE.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check ZYDUSLIFE.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while ZYDUSLIFE.NS trades at ₹1,120.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas ZYDUSLIFE.NS's P/E ratio is 26.22. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to ZYDUSLIFE.NS's ROE of +0.16%. Regarding short-term risk, COHANCE.NS is more volatile compared to ZYDUSLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check ZYDUSLIFE.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, LUPIN.NS has a market cap of 1T. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while LUPIN.NS trades at ₹2,201.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas LUPIN.NS's P/E ratio is 17.29. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to LUPIN.NS's ROE of +0.26%. Regarding short-term risk, COHANCE.NS is more volatile compared to LUPIN.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check LUPIN.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, LUPIN.BO has a market cap of 1T. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while LUPIN.BO trades at ₹2,193.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas LUPIN.BO's P/E ratio is 17.21. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to LUPIN.BO's ROE of +0.26%. Regarding short-term risk, COHANCE.NS is more volatile compared to LUPIN.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check LUPIN.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, DRREDDY.BO has a market cap of 987.2B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while DRREDDY.BO trades at ₹1,175.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas DRREDDY.BO's P/E ratio is 22.85. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to DRREDDY.BO's ROE of +0.09%. Regarding short-term risk, COHANCE.NS is more volatile compared to DRREDDY.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check DRREDDY.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, MANKIND.NS has a market cap of 984.6B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while MANKIND.NS trades at ₹2,384.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas MANKIND.NS's P/E ratio is 45.61. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, COHANCE.NS is more volatile compared to MANKIND.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check MANKIND.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, LAURUSLABS.BO has a market cap of 979.7B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while LAURUSLABS.BO trades at ₹1,814.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas LAURUSLABS.BO's P/E ratio is 89.35. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to LAURUSLABS.BO's ROE of +0.21%. Regarding short-term risk, COHANCE.NS is more volatile compared to LAURUSLABS.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check LAURUSLABS.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, MANKIND.BO has a market cap of 979.5B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while MANKIND.BO trades at ₹2,372.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas MANKIND.BO's P/E ratio is 45.37. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, COHANCE.NS is more volatile compared to MANKIND.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check MANKIND.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, DRREDDY.NS has a market cap of 978.5B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while DRREDDY.NS trades at ₹1,174.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas DRREDDY.NS's P/E ratio is 29.58. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to DRREDDY.NS's ROE of +0.09%. Regarding short-term risk, COHANCE.NS is more volatile compared to DRREDDY.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check DRREDDY.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, LAURUSLABS.NS has a market cap of 973.5B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while LAURUSLABS.NS trades at ₹1,802.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas LAURUSLABS.NS's P/E ratio is 88.94. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to LAURUSLABS.NS's ROE of +0.21%. Regarding short-term risk, COHANCE.NS is more volatile compared to LAURUSLABS.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check LAURUSLABS.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, AUROPHARMA.NS has a market cap of 932.9B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while AUROPHARMA.NS trades at ₹1,621.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas AUROPHARMA.NS's P/E ratio is 25.33. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, COHANCE.NS is more volatile compared to AUROPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check AUROPHARMA.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, AUROPHARMA.BO has a market cap of 931.7B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while AUROPHARMA.BO trades at ₹1,619.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas AUROPHARMA.BO's P/E ratio is 25.31. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, COHANCE.NS is more volatile compared to AUROPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check AUROPHARMA.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, GLENMARK.BO has a market cap of 666.1B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while GLENMARK.BO trades at ₹2,306.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas GLENMARK.BO's P/E ratio is 36.21. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to GLENMARK.BO's ROE of +0.19%. Regarding short-term risk, COHANCE.NS is more volatile compared to GLENMARK.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check GLENMARK.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, GLENMARK.NS has a market cap of 654.1B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while GLENMARK.NS trades at ₹2,317.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas GLENMARK.NS's P/E ratio is 37.99. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to GLENMARK.NS's ROE of +0.19%. Regarding short-term risk, COHANCE.NS is more volatile compared to GLENMARK.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check GLENMARK.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, ALKEM.NS has a market cap of 645.7B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while ALKEM.NS trades at ₹5,400.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas ALKEM.NS's P/E ratio is 29.89. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to ALKEM.NS's ROE of +0.16%. Regarding short-term risk, COHANCE.NS is more volatile compared to ALKEM.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check ALKEM.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, ALKEM.BO has a market cap of 644.4B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while ALKEM.BO trades at ₹5,397.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas ALKEM.BO's P/E ratio is 29.91. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to ALKEM.BO's ROE of +0.16%. Regarding short-term risk, COHANCE.NS is more volatile compared to ALKEM.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check ALKEM.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, IPCALAB.BO has a market cap of 488.3B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while IPCALAB.BO trades at ₹1,910.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas IPCALAB.BO's P/E ratio is 36.09. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to IPCALAB.BO's ROE of +0.16%. Regarding short-term risk, COHANCE.NS is more volatile compared to IPCALAB.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check IPCALAB.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, IPCALAB.NS has a market cap of 484.9B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while IPCALAB.NS trades at ₹1,911.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas IPCALAB.NS's P/E ratio is 35.90. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to IPCALAB.NS's ROE of +0.16%. Regarding short-term risk, COHANCE.NS is more volatile compared to IPCALAB.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check IPCALAB.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, GLAND.NS has a market cap of 465.1B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while GLAND.NS trades at ₹2,819.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas GLAND.NS's P/E ratio is 41.12. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to GLAND.NS's ROE of +0.11%. Regarding short-term risk, COHANCE.NS is more volatile compared to GLAND.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check GLAND.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, GLAND.BO has a market cap of 465B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while GLAND.BO trades at ₹2,820.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas GLAND.BO's P/E ratio is 41.15. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to GLAND.BO's ROE of +0.11%. Regarding short-term risk, COHANCE.NS is more volatile compared to GLAND.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check GLAND.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, AJANTPHARM.NS has a market cap of 454.7B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while AJANTPHARM.NS trades at ₹3,639.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas AJANTPHARM.NS's P/E ratio is 40.12. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, COHANCE.NS is more volatile compared to AJANTPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check AJANTPHARM.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, AJANTPHARM.BO has a market cap of 454.2B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while AJANTPHARM.BO trades at ₹3,640.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas AJANTPHARM.BO's P/E ratio is 40.12. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, COHANCE.NS is more volatile compared to AJANTPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check AJANTPHARM.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to SUVENPHAR.NS's ROE of +0.05%. Regarding short-term risk, COHANCE.NS is more volatile compared to SUVENPHAR.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check SUVENPHAR.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to SUVENPHAR.BO's ROE of +0.16%. Regarding short-term risk, COHANCE.NS is more volatile compared to SUVENPHAR.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check SUVENPHAR.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, JBCHEPHARM.NS has a market cap of 387.9B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while JBCHEPHARM.NS trades at ₹2,416.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas JBCHEPHARM.NS's P/E ratio is 52.07. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, COHANCE.NS is less volatile compared to JBCHEPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for COHANCE.NS.Check JBCHEPHARM.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, EMCURE.NS has a market cap of 353.4B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while EMCURE.NS trades at ₹1,863.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas EMCURE.NS's P/E ratio is 34.06. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to EMCURE.NS's ROE of +0.21%. Regarding short-term risk, COHANCE.NS is more volatile compared to EMCURE.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check EMCURE.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, NEULANDLAB.BO has a market cap of 299.5B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while NEULANDLAB.BO trades at ₹23,294.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas NEULANDLAB.BO's P/E ratio is 59.22. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to NEULANDLAB.BO's ROE of +0.28%. Regarding short-term risk, COHANCE.NS is more volatile compared to NEULANDLAB.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check NEULANDLAB.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, NEULANDLAB.NS has a market cap of 298.9B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while NEULANDLAB.NS trades at ₹23,301.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas NEULANDLAB.NS's P/E ratio is 59.07. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to NEULANDLAB.NS's ROE of +0.28%. Regarding short-term risk, COHANCE.NS is more volatile compared to NEULANDLAB.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check NEULANDLAB.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, PPLPHARMA.NS has a market cap of 283.1B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while PPLPHARMA.NS trades at ₹213.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas PPLPHARMA.NS's P/E ratio is -182.45. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, COHANCE.NS is more volatile compared to PPLPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check PPLPHARMA.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, PPLPHARMA.BO has a market cap of 282.4B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while PPLPHARMA.BO trades at ₹213.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas PPLPHARMA.BO's P/E ratio is -182.35. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, COHANCE.NS is more volatile compared to PPLPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check PPLPHARMA.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to PEL.NS's ROE of +0.01%. Regarding short-term risk, COHANCE.NS is less volatile compared to PEL.NS. This indicates lower risk in terms of short-term price fluctuations for COHANCE.NS.Check PEL.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, GRANULES.BO has a market cap of 213.7B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while GRANULES.BO trades at ₹858.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas GRANULES.BO's P/E ratio is 32.83. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to GRANULES.BO's ROE of +0.16%. Regarding short-term risk, COHANCE.NS is more volatile compared to GRANULES.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check GRANULES.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, GRANULES.NS has a market cap of 212.6B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while GRANULES.NS trades at ₹858.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas GRANULES.NS's P/E ratio is 32.60. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to GRANULES.NS's ROE of +0.16%. Regarding short-term risk, COHANCE.NS is more volatile compared to GRANULES.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check GRANULES.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, CAPLIPOINT.BO has a market cap of 192.5B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while CAPLIPOINT.BO trades at ₹2,563.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas CAPLIPOINT.BO's P/E ratio is 29.73. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, COHANCE.NS is more volatile compared to CAPLIPOINT.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check CAPLIPOINT.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, CAPLIPOINT.NS has a market cap of 192.3B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while CAPLIPOINT.NS trades at ₹2,560.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas CAPLIPOINT.NS's P/E ratio is 29.73. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, COHANCE.NS is more volatile compared to CAPLIPOINT.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check CAPLIPOINT.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, ASTRAZEN.NS has a market cap of 185.4B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while ASTRAZEN.NS trades at ₹7,415.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas ASTRAZEN.NS's P/E ratio is 98.86. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to ASTRAZEN.NS's ROE of +0.20%. Regarding short-term risk, COHANCE.NS is more volatile compared to ASTRAZEN.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check ASTRAZEN.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, ASTRAZEN.BO has a market cap of 185.4B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while ASTRAZEN.BO trades at ₹7,410.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas ASTRAZEN.BO's P/E ratio is 98.79. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to ASTRAZEN.BO's ROE of +0.20%. Regarding short-term risk, COHANCE.NS is more volatile compared to ASTRAZEN.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check ASTRAZEN.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, ERIS.NS has a market cap of 184.1B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while ERIS.NS trades at ₹1,328.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas ERIS.NS's P/E ratio is 37.57. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, COHANCE.NS is more volatile compared to ERIS.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check ERIS.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, ERIS.BO has a market cap of 183.8B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while ERIS.BO trades at ₹1,325.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas ERIS.BO's P/E ratio is 42.98. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, COHANCE.NS is more volatile compared to ERIS.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check ERIS.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, COHANCE.BO has a market cap of 181.5B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while COHANCE.BO trades at ₹462.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas COHANCE.BO's P/E ratio is 150.25. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to COHANCE.BO's ROE of +0.03%. Regarding short-term risk, COHANCE.NS is more volatile compared to COHANCE.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check COHANCE.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, ALIVUS.NS has a market cap of 165.8B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while ALIVUS.NS trades at ₹1,350.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas ALIVUS.NS's P/E ratio is 26.78. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to ALIVUS.NS's ROE of +0.20%. Regarding short-term risk, COHANCE.NS is more volatile compared to ALIVUS.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check ALIVUS.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, ALIVUS.BO has a market cap of 165.5B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while ALIVUS.BO trades at ₹1,348.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas ALIVUS.BO's P/E ratio is 30.00. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to ALIVUS.BO's ROE of +0.10%. Regarding short-term risk, COHANCE.NS is more volatile compared to ALIVUS.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check ALIVUS.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, APLLTD.NS has a market cap of 161.5B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while APLLTD.NS trades at ₹821.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas APLLTD.NS's P/E ratio is 21.51. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, COHANCE.NS is more volatile compared to APLLTD.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check APLLTD.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, APLLTD.BO has a market cap of 161.3B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while APLLTD.BO trades at ₹820.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas APLLTD.BO's P/E ratio is 21.48. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, COHANCE.NS is more volatile compared to APLLTD.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check APLLTD.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, SHILPAMED.NS has a market cap of 159.4B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while SHILPAMED.NS trades at ₹814.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas SHILPAMED.NS's P/E ratio is 51.78. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to SHILPAMED.NS's ROE of +0.12%. Regarding short-term risk, COHANCE.NS is more volatile compared to SHILPAMED.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check SHILPAMED.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, NATCOPHARM.NS has a market cap of 158B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while NATCOPHARM.NS trades at ₹882.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas NATCOPHARM.NS's P/E ratio is 13.80. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to NATCOPHARM.NS's ROE of +0.13%. Regarding short-term risk, COHANCE.NS is more volatile compared to NATCOPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check NATCOPHARM.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, NATCOPHARM.BO has a market cap of 158B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while NATCOPHARM.BO trades at ₹882.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas NATCOPHARM.BO's P/E ratio is 13.81. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to NATCOPHARM.BO's ROE of +0.13%. Regarding short-term risk, COHANCE.NS is more volatile compared to NATCOPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check NATCOPHARM.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, JUBLPHARMA.NS has a market cap of 139.4B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while JUBLPHARMA.NS trades at ₹880.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas JUBLPHARMA.NS's P/E ratio is 36.48. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to JUBLPHARMA.NS's ROE of +0.05%. Regarding short-term risk, COHANCE.NS is more volatile compared to JUBLPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check JUBLPHARMA.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, JUBLPHARMA.BO has a market cap of 139.4B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while JUBLPHARMA.BO trades at ₹879.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas JUBLPHARMA.BO's P/E ratio is 36.48. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to JUBLPHARMA.BO's ROE of +0.05%. Regarding short-term risk, COHANCE.NS is more volatile compared to JUBLPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check JUBLPHARMA.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, COHANCE.NS is more volatile compared to GLS.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check GLS.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to GLS.BO's ROE of +0.21%. Regarding short-term risk, COHANCE.NS is more volatile compared to GLS.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check GLS.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, SUDEEPPHRM.NS has a market cap of 125.6B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while SUDEEPPHRM.NS trades at ₹1,111.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas SUDEEPPHRM.NS's P/E ratio is 128.53. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, COHANCE.NS is less volatile compared to SUDEEPPHRM.NS. This indicates lower risk in terms of short-term price fluctuations for COHANCE.NS.Check SUDEEPPHRM.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, VIYASH.NS has a market cap of 120.4B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while VIYASH.NS trades at ₹275.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas VIYASH.NS's P/E ratio is 66.33. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to VIYASH.NS's ROE of +0.13%. Regarding short-term risk, COHANCE.NS is more volatile compared to VIYASH.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check VIYASH.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, AKUMS.NS has a market cap of 114.8B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while AKUMS.NS trades at ₹750.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas AKUMS.NS's P/E ratio is 39.70. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to AKUMS.NS's ROE of +0.09%. Regarding short-term risk, COHANCE.NS is more volatile compared to AKUMS.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check AKUMS.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, COHANCE.NS is less volatile compared to CAPPL.BO. This indicates lower risk in terms of short-term price fluctuations for COHANCE.NS.Check CAPPL.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, PGHL.BO has a market cap of 97B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while PGHL.BO trades at ₹5,834.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas PGHL.BO's P/E ratio is 29.64. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to PGHL.BO's ROE of +0.59%. Regarding short-term risk, COHANCE.NS is more volatile compared to PGHL.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check PGHL.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, PGHL.NS has a market cap of 96.7B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while PGHL.NS trades at ₹5,828.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas PGHL.NS's P/E ratio is 29.61. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to PGHL.NS's ROE of +0.59%. Regarding short-term risk, COHANCE.NS is more volatile compared to PGHL.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check PGHL.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, STAR.NS has a market cap of 90.9B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while STAR.NS trades at ₹986.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas STAR.NS's P/E ratio is 14.83. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to STAR.NS's ROE of +0.22%. Regarding short-term risk, COHANCE.NS is more volatile compared to STAR.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check STAR.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, STAR.BO has a market cap of 90.6B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while STAR.BO trades at ₹985.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas STAR.BO's P/E ratio is 14.83. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to STAR.BO's ROE of +0.22%. Regarding short-term risk, COHANCE.NS is more volatile compared to STAR.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check STAR.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, SUVEN.NS has a market cap of 85.1B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while SUVEN.NS trades at ₹373.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas SUVEN.NS's P/E ratio is -30.94. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to SUVEN.NS's ROE of -1.12%. Regarding short-term risk, COHANCE.NS is less volatile compared to SUVEN.NS. This indicates lower risk in terms of short-term price fluctuations for COHANCE.NS.Check SUVEN.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, SUVEN.BO has a market cap of 83.9B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while SUVEN.BO trades at ₹372.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas SUVEN.BO's P/E ratio is -30.01. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to SUVEN.BO's ROE of -1.12%. Regarding short-term risk, COHANCE.NS is less volatile compared to SUVEN.BO. This indicates lower risk in terms of short-term price fluctuations for COHANCE.NS.Check SUVEN.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, SHILPAMED.BO has a market cap of 79.7B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while SHILPAMED.BO trades at ₹814.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas SHILPAMED.BO's P/E ratio is 53.44. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to SHILPAMED.BO's ROE of +0.12%. Regarding short-term risk, COHANCE.NS is more volatile compared to SHILPAMED.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check SHILPAMED.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, AARTIPHARM.NS has a market cap of 74.1B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while AARTIPHARM.NS trades at ₹816.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas AARTIPHARM.NS's P/E ratio is 28.23. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to AARTIPHARM.NS's ROE of +0.10%. Regarding short-term risk, COHANCE.NS is more volatile compared to AARTIPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check AARTIPHARM.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, AARTIPHARM.BO has a market cap of 73.7B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while AARTIPHARM.BO trades at ₹816.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas AARTIPHARM.BO's P/E ratio is 39.41. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to AARTIPHARM.BO's ROE of +0.10%. Regarding short-term risk, COHANCE.NS is more volatile compared to AARTIPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check AARTIPHARM.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, SPARC.NS has a market cap of 63.8B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while SPARC.NS trades at ₹196.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas SPARC.NS's P/E ratio is 4.11. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to SPARC.NS's ROE of +3.19%. Regarding short-term risk, COHANCE.NS is more volatile compared to SPARC.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check SPARC.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, SPARC.BO has a market cap of 63.7B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while SPARC.BO trades at ₹196.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas SPARC.BO's P/E ratio is 4.11. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to SPARC.BO's ROE of +3.19%. Regarding short-term risk, COHANCE.NS is more volatile compared to SPARC.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check SPARC.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, INNOVACAP.NS has a market cap of 62.3B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while INNOVACAP.NS trades at ₹1,088.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas INNOVACAP.NS's P/E ratio is 51.18. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to INNOVACAP.NS's ROE of +0.15%. Regarding short-term risk, COHANCE.NS is more volatile compared to INNOVACAP.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check INNOVACAP.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, BLISSGVS.BO has a market cap of 62.1B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while BLISSGVS.BO trades at ₹582.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas BLISSGVS.BO's P/E ratio is 48.32. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to BLISSGVS.BO's ROE of +0.12%. Regarding short-term risk, COHANCE.NS is less volatile compared to BLISSGVS.BO. This indicates lower risk in terms of short-term price fluctuations for COHANCE.NS.Check BLISSGVS.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, BLISSGVS.NS has a market cap of 61.4B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while BLISSGVS.NS trades at ₹579.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas BLISSGVS.NS's P/E ratio is 48.06. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to BLISSGVS.NS's ROE of +0.12%. Regarding short-term risk, COHANCE.NS is less volatile compared to BLISSGVS.NS. This indicates lower risk in terms of short-term price fluctuations for COHANCE.NS.Check BLISSGVS.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, FDC.NS has a market cap of 56.8B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while FDC.NS trades at ₹348.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas FDC.NS's P/E ratio is 20.16. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, COHANCE.NS is more volatile compared to FDC.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check FDC.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, FDC.BO has a market cap of 56.7B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while FDC.BO trades at ₹348.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas FDC.BO's P/E ratio is 20.14. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to FDC.BO's ROE of +0.12%. Regarding short-term risk, COHANCE.NS is more volatile compared to FDC.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check FDC.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, MOREPENLAB.BO has a market cap of 52.6B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while MOREPENLAB.BO trades at ₹96.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas MOREPENLAB.BO's P/E ratio is 55.49. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to MOREPENLAB.BO's ROE of +0.12%. Regarding short-term risk, COHANCE.NS is less volatile compared to MOREPENLAB.BO. This indicates lower risk in terms of short-term price fluctuations for COHANCE.NS.Check MOREPENLAB.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, MOREPENLAB.NS has a market cap of 52.6B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while MOREPENLAB.NS trades at ₹96.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas MOREPENLAB.NS's P/E ratio is 55.50. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to MOREPENLAB.NS's ROE of +0.12%. Regarding short-term risk, COHANCE.NS is less volatile compared to MOREPENLAB.NS. This indicates lower risk in terms of short-term price fluctuations for COHANCE.NS.Check MOREPENLAB.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, ORCHPHARMA.NS has a market cap of 50.8B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while ORCHPHARMA.NS trades at ₹1,002.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas ORCHPHARMA.NS's P/E ratio is 161.62. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, COHANCE.NS is less volatile compared to ORCHPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for COHANCE.NS.Check ORCHPHARMA.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to SEQUENT.BO's ROE of +0.09%. Regarding short-term risk, COHANCE.NS is more volatile compared to SEQUENT.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check SEQUENT.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to SEQUENT.NS's ROE of +0.09%. Regarding short-term risk, COHANCE.NS is more volatile compared to SEQUENT.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check SEQUENT.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, ORCHPHARMA.BO has a market cap of 50.5B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while ORCHPHARMA.BO trades at ₹997.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas ORCHPHARMA.BO's P/E ratio is 77.68. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to ORCHPHARMA.BO's ROE of +0.01%. Regarding short-term risk, COHANCE.NS is more volatile compared to ORCHPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check ORCHPHARMA.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, IOLCP.BO has a market cap of 49.8B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while IOLCP.BO trades at ₹169.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas IOLCP.BO's P/E ratio is 33.25. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to IOLCP.BO's ROE of +0.10%. Regarding short-term risk, COHANCE.NS is less volatile compared to IOLCP.BO. This indicates lower risk in terms of short-term price fluctuations for COHANCE.NS.Check IOLCP.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, IOLCP.NS has a market cap of 49.8B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while IOLCP.NS trades at ₹169.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas IOLCP.NS's P/E ratio is 33.37. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to IOLCP.NS's ROE of +0.10%. Regarding short-term risk, COHANCE.NS is less volatile compared to IOLCP.NS. This indicates lower risk in terms of short-term price fluctuations for COHANCE.NS.Check IOLCP.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, RPGLIFE.BO has a market cap of 43.9B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while RPGLIFE.BO trades at ₹2,634.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas RPGLIFE.BO's P/E ratio is 37.83. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, COHANCE.NS is more volatile compared to RPGLIFE.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check RPGLIFE.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, RPGLIFE.NS has a market cap of 43.6B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while RPGLIFE.NS trades at ₹2,636.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas RPGLIFE.NS's P/E ratio is 37.86. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, COHANCE.NS is more volatile compared to RPGLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check RPGLIFE.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, GUFICBIO.BO has a market cap of 43.4B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while GUFICBIO.BO trades at ₹432.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas GUFICBIO.BO's P/E ratio is 67.64. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to GUFICBIO.BO's ROE of +0.11%. Regarding short-term risk, COHANCE.NS is more volatile compared to GUFICBIO.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check GUFICBIO.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, GUFICBIO.NS has a market cap of 43.3B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while GUFICBIO.NS trades at ₹431.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas GUFICBIO.NS's P/E ratio is 67.42. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to GUFICBIO.NS's ROE of +0.11%. Regarding short-term risk, COHANCE.NS is less volatile compared to GUFICBIO.NS. This indicates lower risk in terms of short-term price fluctuations for COHANCE.NS.Check GUFICBIO.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, GUJTHEM.NS has a market cap of 41.5B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while GUJTHEM.NS trades at ₹381.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas GUJTHEM.NS's P/E ratio is 88.65. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to GUJTHEM.NS's ROE of +0.18%. Regarding short-term risk, COHANCE.NS is more volatile compared to GUJTHEM.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check GUJTHEM.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, GUJTHEM.BO has a market cap of 41.5B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while GUJTHEM.BO trades at ₹380.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas GUJTHEM.BO's P/E ratio is 29.35. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to GUJTHEM.BO's ROE of +0.18%. Regarding short-term risk, COHANCE.NS is less volatile compared to GUJTHEM.BO. This indicates lower risk in terms of short-term price fluctuations for COHANCE.NS.Check GUJTHEM.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, AARTIDRUGS.BO has a market cap of 38.1B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while AARTIDRUGS.BO trades at ₹417.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas AARTIDRUGS.BO's P/E ratio is 19.66. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to AARTIDRUGS.BO's ROE of +0.13%. Regarding short-term risk, COHANCE.NS is more volatile compared to AARTIDRUGS.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check AARTIDRUGS.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, AARTIDRUGS.NS has a market cap of 38.1B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while AARTIDRUGS.NS trades at ₹417.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas AARTIDRUGS.NS's P/E ratio is 19.64. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to AARTIDRUGS.NS's ROE of +0.13%. Regarding short-term risk, COHANCE.NS is more volatile compared to AARTIDRUGS.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check AARTIDRUGS.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, UNICHEMLAB.BO has a market cap of 37.1B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while UNICHEMLAB.BO trades at ₹525.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas UNICHEMLAB.BO's P/E ratio is 14.64. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, COHANCE.NS is more volatile compared to UNICHEMLAB.BO. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check UNICHEMLAB.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, UNICHEMLAB.NS has a market cap of 37B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while UNICHEMLAB.NS trades at ₹526.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas UNICHEMLAB.NS's P/E ratio is 14.65. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, COHANCE.NS is more volatile compared to UNICHEMLAB.NS. This indicates higher risk in terms of short-term price fluctuations for COHANCE.NS.Check UNICHEMLAB.NS's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, NOVARTIND.BO has a market cap of 35.1B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while NOVARTIND.BO trades at ₹1,423.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas NOVARTIND.BO's P/E ratio is 37.04. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, COHANCE.NS is less volatile compared to NOVARTIND.BO. This indicates lower risk in terms of short-term price fluctuations for COHANCE.NS.Check NOVARTIND.BO's competition here

Cohance Lifesciences Limited (NSE: COHANCE.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COHANCE.NS stands at 181.9B. In comparison, NOVARTIND.NS has a market cap of 35B. Regarding current trading prices, COHANCE.NS is priced at ₹463.00 on the NSE, while NOVARTIND.NS trades at ₹1,418.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COHANCE.NS currently has a P/E ratio of 143.81, whereas NOVARTIND.NS's P/E ratio is 36.92. In terms of profitability, COHANCE.NS's ROE is +0.03%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, COHANCE.NS is less volatile compared to NOVARTIND.NS. This indicates lower risk in terms of short-term price fluctuations for COHANCE.NS.Check NOVARTIND.NS's competition here